002019 Yifan Pharmaceutical
- 13.36
- +0.09+0.68%
Yifan Pharmaceutical News
Investors Still Aren't Entirely Convinced By Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Revenues Despite 27% Price Jump
Yifan Pharmaceutical Co., Ltd. (SZSE:002019) shareholders would be excited to see that the share price has had a great month, posting a 27% gain and recovering from prior weakness. The bad news is
Yifan Pharmaceutical Unit Gets Authorization to Sell Circulation Supplement in Singapore
Yifan Pharmaceutical's (SHE:002019) unit, SciGen, received approval from Singapore's Health Sciences Authority to register and market its Ginkgo leaf pills in the city-state, according to a filing wit
Yifan Pharmaceutical (002019.SZ): Diet drug products are currently in the preclinical research stage
Gelonghui, May 8, 丨 Yifan Pharmaceutical (002019.SZ) held a performance briefing on May 7, 2024 to discuss “Does the company have diet medicine products?” The company replied that the company's diet drug products are currently in the pre-clinical research stage.
Yifan Pharmaceutical (002019.SZ): Heroda is expected to achieve annual revenue of 500 to 1 billion yuan
Gelonghui, May 8, 丨 Yifan Pharmaceutical (002019.SZ) held a performance briefing on May 7, 2024 to discuss “How much revenue is Heroda expected to contribute each year?” The company replied that according to the current sales situation, it is expected to achieve annual revenue of 500 to 1 billion yuan.
Yifan Pharmaceutical (002019.SZ): The Hangzhou production base is expected to have some production capacity between the end of 2024 and the first quarter of 2025
Gelonghui, May 8, 丨 Yifan Pharmaceutical (002019.SZ) held a performance briefing on May 7, 2024, to discuss “What stage has the Hangzhou Synthetic Biology Industrial Park reached? Can the first phase be tested?” The company replied that the Hangzhou production base is under construction according to the plan and is expected to have some production capacity between the end of 2024 and the first quarter of 2025.
Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps
Yifan Pharmaceutical (SHE:002019) unit Sichuan Defeng Pharmaceutical's emestine fumarate sustained-release capsules passed the consistency evaluation by China's National Medical Products Administratio
Yifan Pharmaceutical's Unit Gets Nod to Register Nimodipine Injection
Yifan Pharmaceutical's (SHE:002019) unit, Liaoning Yifan Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for its nimodipine injection, th
Three Drugs of Yifan Pharmaceutical's Unit Placed in China's Centralized Procurement
Three drugs produced by Yifan Pharmaceutical's (SHE:002019) unit, Hefei Yifan Biopharmaceutical, were included in China's National Centralized Drug Procurement, the company said in its filing on the S
Yifan Pharmaceutical (002019.SZ): The disclosure period for the first quarter report was changed to April 24
Gelonghui, April 22丨Yifan Pharmaceutical (002019.SZ) announced that the original scheduled disclosure period for the “2024 First Quarter Report” was April 30, 2024. Now that the preparation of the “2024 First Quarter Report” has been completed ahead of schedule, it has been decided to change the disclosure period of the company's “2024 First Quarter Report” to April 24, 2024.
Does This Valuation Of Yifan Pharmaceutical Co., Ltd. (SZSE:002019) Imply Investors Are Overpaying?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Yifan Pharmaceutical fair value estimate is CN¥8.89 Yifan Pharmaceutical is estimated to be 23% overvalued based on current share price of CN
Yifan Pharmaceutical (002019.SZ) issued 2023 annual results, with a net loss of 551 million yuan, which changed from profit to loss over the previous year
Yifan Pharmaceutical (002019.SZ) released its 2023 annual report, with revenue of 4,068 billion yuan, compared with...
Yifan Pharmaceutical (002019.SZ): Currently, all preparations for overseas markets are supplied by the US CDMO company
Gelonghui, April 3: An investor asked Yifan Pharmaceutical (002019.SZ) on the investor interactive platform, “Is the F-627 preparation sold in Europe supplied by the US or domestically?” The company replied that currently all preparations are supplied to overseas markets by the US CDMO company.
Yifan Pharmaceutical (002019.SZ): The number of shareholders of the company as of March 20, 2024 was 40,605
Gelonghui, April 3 | Yifan Pharmaceutical (002019.SZ) said on the investor interactive platform that as of March 20, 2024, the number of shareholders of the company was 40,605.
Yifan Pharmaceutical (002019.SZ): The first synthetic biology R&D project is expected to be completed by the end of 2024
Gelonghui April 3 丨 An investor asked Yifan Pharmaceutical (002019.SZ) on the investor interactive platform, “Has the Hangzhou factory begun trial production? In addition to vitamin b5, when will the company's other vitamins with advanced technology and cost advantages be mass-produced and turned into productivity?” The company replied that the first synthetic biology research and development project is expected to be completed by the end of 2024.
Yifan Pharmaceutical Gets EU Nod to Sell Ryzneuta Drug
Yifan Pharmaceutical (SHE:002019) subsidiary, Evive Biotechnology Ireland, has secured regulatory approval from the European Union to market its drug Ryzneuta, according to a filing with the Shenzhen
Retail Investors Are Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Biggest Owners and Were Hit After Market Cap Dropped CN¥1.2b
Key Insights Significant control over Yifan Pharmaceutical by retail investors implies that the general public has more power to influence management and governance-related decisions A total of 25 i
Yifan Pharmaceutical (002019.SZ) Holdings subsidiary's products under development were approved for listing by the European Commission
Yifan Pharmaceutical (002019.SZ) announced that its holding subsidiary Evive Biotec...
Market Might Still Lack Some Conviction On Yifan Pharmaceutical Co., Ltd. (SZSE:002019) Even After 28% Share Price Boost
Those holding Yifan Pharmaceutical Co., Ltd. (SZSE:002019) shares would be relieved that the share price has rebounded 28% in the last thirty days, but it needs to keep going to repair the recent dama
Yifan Pharmaceutical (002019.SZ): Wholly-owned subsidiary once again passed the high-tech enterprise certification
Gelonghui, Feb. 29丨Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary Anqing Xinfu Chemical Co., Ltd. recently received a “High-tech Enterprise Certificate” jointly issued by the Anhui Provincial Department of Science and Technology, the Anhui Provincial Department of Finance, and the Anhui Provincial Taxation Bureau of the State Administration of Taxation. The wholly-owned subsidiary Anqing Xinfu Hi-Tech Certification was re-certified after the original “High-tech Enterprise Certificate” expired.
Yifan Pharmaceutical (002019.SZ): Maqin cough tablets obtained registration approval in Singapore
Gelonghui Feb. 29丨Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary SciGen Pte. Ltd. (“Sai Zhen Company” for short) recently received a proprietary Chinese medicine registration approval from the Singapore Health Sciences Authority (Health Sciences Authority) to approve the marketing and sale of the company's exclusive medical insurance product, Maqin cough tablets in Singapore. Maqin cough relief granules are derived from the clinical experience of famous traditional Chinese medicine in Anhui Province. They are added and reduced based on “Ma Xing Shi Gan Soup”. They have been used clinically for many years before marketing to clear the lungs and relieve phlegm, relieve cough and relieve asthma, prevent,
Analysis
Price Target
No Data
